Results 171 to 180 of about 6,309 (194)
Some of the next articles are maybe not open access.
Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy
American Journal of Cardiovascular Drugs, 2021Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease characterized by the aggregation and deposition of amyloidogenic misfolded transthyretin (TTR) in the myocardium. The gradual accumulation of insoluble TTR amyloid fibrils can result in restrictive cardiomyopathy and heart failure. Tafamidis (Vyndaqel®; Vyndamax®),
openaire +2 more sources
Tafamidis for transthyretin amyloidosis
Drugs of Today, 2012Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal.
openaire +2 more sources
Tafamidis (Vyndaqel): A Light for FAP Patients
ChemMedChem, 2013Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer. Tafamidis acts in a similar way to the natural hormone T4, prevents TTR amyloid fibril formation, and offers a potential alternative to liver transplantation for the treatment of patients with TTR familial amyloid polyneuropathies ...
NENCETTI, SUSANNA +2 more
openaire +3 more sources
Tafamidis use in amyloid cardiomyopathy
Journal of Prescribing PracticeDeborah Robertson provides an overview of recently published articles that may be of interest to non-medical prescribers. Should you wish to look at any of the papers in more detail, a full reference is provided
openaire +1 more source